Examination of Sleep & Family Functioning in Pediatric Craniopharyngioma

Status Completed

Clinical Trial Summary

Pediatric craniopharyngioma patients experience significant endocrine and sleep dysregulation difficulties. Sleep is a crucial part of children's healthy development, and sleep difficulties are associated with severe functional morbidity. Insufficient sleep, excessive daytime sleepiness, and poor sleep quality have all been significantly related to academic, behavioral, and emotional functioning in children and adolescents. Ecological momentary assessments (EMA) will be used to collect observational data.

EMA data will be collected twice daily for one week. For the morning EMA administration, participants will be asked about their sleep. During the evening administration, participants will be asked about their daytime sleepiness, overall well-being, and family functioning. Covariates also administered during the evening administration include medication administration (Y/N) and total screen time. At the end of the EMA data collection period (on day 7 OR 8), participants will be sent a survey asking them to report - anonymously - their overall experience and satisfaction with the EMA data collection method.

Clinical Trial Description

After recruitment and informed consent/assent is obtained for the current study, participants will be asked to complete a questionnaire battery online (via REDCap) assessing sleep habits, daytime sleepiness, family routines, family functioning, and overall quality of life in the past six months. The relationship between subjective sleep ratings obtained from the parent craniopharyngioma study at St. Jude (RT2CR) at diagnosis and 3 months later (T1 and T2) and family functioning/routines at the follow-up study (T3) will be assessed. The researchers have permission to use data for all participants who consent to participate in this follow-up EMA study.

Children will be sent electronic surveys two times per day (i.e., morning and evening) for seven days using Ilumivu software (https://ilumivu.com/mema-demo). Ilumivu is an established EMA tool that offers an in-mobile app for participants to respond to questionnaires in real time with limited burden. This application will send notifications to participants to remind them to complete surveys and record response times for each survey. ;

Study Design

Related Conditions & MeSH terms

Craniopharyngioma

Clinical Trial Details

NCT number	NCT03330080
Study type	Observational
Source	St. Jude Children's Research Hospital
Contact
Status	Completed
Phase
Start date	February 12, 2018
Completion date	January 29, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT00949156` - Tumor Classification and Its Application in Surgical Treatment of Craniopharyngioma	Phase 1
Recruiting	`NCT05465174` - Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults	Phase 2
Recruiting	`NCT05525273` - Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma	Phase 2
Completed	`NCT02849743` - Intranasal Oxytocin in Hypothalamic Obesity	Phase 2
Completed	`NCT01272622` - Prospective Study of Children and Adolescents With Craniopharyngioma	N/A
Recruiting	`NCT04158284` - Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Recruiting	`NCT06217848` - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study	Early Phase 1
Completed	`NCT01881854` - Sleep Wake and Melatonin Pattern in Craniopharyngioma	N/A
Active, not recruiting	`NCT00517959` - SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors	Phase 3
Not yet recruiting	`NCT06299891` - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity	Phase 2
Completed	`NCT02842723` - Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)	Phase 2
Recruiting	`NCT02792582` - A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection	Phase 2
Completed	`NCT01484873` - Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor	Phase 2
Withdrawn	`NCT03708913` - Neuromodulation for Hypothalamic Obesity	N/A
Completed	`NCT02162732` - Molecular-Guided Therapy for Childhood Cancer	N/A
Recruiting	`NCT00840047` - Methionine PET/CT Studies In Patients With Cancer	Phase 2
Recruiting	`NCT04087902` - Long-Term Longitudinal QoL in Patients Undergoing EEA
Recruiting	`NCT04648462` - Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology
Completed	`NCT04937335` - Craniopharyngioma With Tumoral Hemorrhage

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms